Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) PB Ratio: 1.03 (As of Jun. 30, 2026) — Near Median


FRA:FDY Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd FRA:FDY
71 GF Score
Price €0.25
GF Value €0.24
! 2 Warning Signs
View Full Analysis

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co PB Ratio?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co FRA:FDY +2.42% 71 PB Ratio is 1.03 as of Jun. 30, 2026, which is 4% below its 10-year median of 1.07. GuruFocus rates FRA:FDY with a GF Score™ of 71/100 and a GF Value™ of €0.24. The stock has 2 warning signs investors should review. Among 922 Drug Manufacturers companies, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks better than 73.43% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-30), Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's share price is €0.254. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Book Value per Share for the quarter that ended in Dec. 2025 was €0.25. Hence, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's PB Ratio of today is 1.03.

Good Sign:

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd stock PB Ratio (=1.01) is close to 1-year low of 1.01.

The historical rank and industry rank for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's PB Ratio or its related term are showing as below:

FRA:FDY' s PB Ratio Range Over the Past 10 Years
Min: 0.72   Med: 1.07   Max: 1.75
Current: 1.01

During the past 13 years, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's highest PB Ratio was 1.75. The lowest was 0.72. And the median was 1.07.

FRA:FDY's PB Ratio is ranked better than
73.43% of 922 companies
in the Drug Manufacturers industry
Industry Median: 1.845 vs FRA:FDY: 1.01

During the past 12 months, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's average Book Value Per Share Growth Rate was -5.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -2.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -1.00% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 11.80% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co was 44.50% per year. The lowest was -2.90% per year. And the median was 7.50% per year.

Back to Basics: PB Ratio


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co  (FRA:FDY) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co PB Ratio Related Terms


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co PB Ratio Historical Data

* Premium members only.

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co PB Ratio Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.43 1.38 0.98 1.02 1.26

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 1.02 1.30 1.47 1.26

FRA:FDY vs ZTS, UTHR: PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's PB Ratio falls into.


FRA:FDY
71GF Score
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd FRA:FDY
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2025)
=0.254/0.246
=1.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 1.03 mean?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a PB Ratio of 1.03 as of Jun. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. This is near median its historical median of 1.07. Over the past decade, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's PB Ratio has ranged from 0.72 to 1.75. According to the industry distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #245 out of 922 companies in the Drug Manufacturers industry, placing it in the top 26.6%.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's PB Ratio too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current PB Ratio of 1.03 is near median its 10-year median of 1.07. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 1.75. The Drug Manufacturers industry median PB Ratio is 1.85. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's value of 1.03 is 44.2% below this industry median. Based on the distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #245 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #245 out of 922 companies for PB Ratio. This puts Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co in the upper half of its industry. The industry median PB Ratio is 1.85. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's value of 1.03 is 44.2% below this benchmark. Historically, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's own PB Ratio has ranged from 0.72 to 1.75 over the past decade. While the company's 10-year median is 1.07 vs. the industry median of 1.85, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.85, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current PB Ratio of 1.03 is 44.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current PB Ratio is 1.03, which is near median its own 10-year median of 1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a current PB Ratio of 1.03. The stock's GF Value™ is €0.24, compared to a current price of €0.25 — trading 5.8% above its estimated fair value. The current PB Ratio is 1.03, which is near median its 10-year median of 1.07 and 44.2% below the Drug Manufacturers industry median of 1.85. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY), the current PB Ratio is 1.03 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued. The current stock price of €0.25 is trading 5.8% above its estimated GF Value™ of €0.24.

Key valuation signals for FRA:FDY:

  • PB Ratio: 1.03 (near median its 10-year median of 1.07)
  • GF Value™: €0.24 vs. price of €0.25 (5.8% above fair value)
  • GF Score™: 71/100 with 2 warning signs
  • Industry Position: 44.2% below the Drug Manufacturers median (#245 of 922)

No single metric tells the full story. See the FRA:FDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description

Other Exchanges 01349:Hong Kong688505:China
Address 308 Cailun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
71GF Score

Get the complete analysis for FRA:FDY

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.25
Price
€0.24
GF Value